EMEA-003223-PIP01-22
Key facts
| Active substance |
N-(6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)-2-((4-fluorobenzyl)thio)pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide (RIST-4721)
|
| Therapeutic area |
Dermatology
|
| Decision number |
P/0275/2022
|
| PIP number |
EMEA-003223-PIP01-22
|
| Pharmaceutical form(s) |
Tablet
|
| Condition(s) / indication(s) |
Treatment of palmoplantar pustulosis
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Aristea Therapeutics, Inc.
Email: pediatrics@aristeatx.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|